Not a good buy right now for an impatient investor: the stock is deeply oversold but still in a bearish momentum regime (MACD negative) with no near-term catalyst.
If you must act today, this is only a speculative “oversold bounce” setup near support (~1.45), not a high-conviction trend-following entry.
Better entry would be after a clear reversal (RSI recovery + MACD improvement) or a catalyst ahead of the next earnings (2026-03-05), neither of which is present now.
Technical Analysis
Trend/Momentum: MACD histogram is -0.0866 (below 0) and only “negatively contracting,” which suggests bearish momentum is easing but not reversed.
Overbought/Oversold: RSI(6) at ~10.16 = extremely oversold, increasing the odds of a short-term bounce, but oversold can persist in weak names.
Moving averages: Converging MAs indicates selling pressure may be stabilizing, but not a confirmed uptrend.
Key levels: Pre-market ~1.47 is sitting just above S1 (1.448). A break below S1 increases risk toward S2 (1.297). Upside reaction levels: Pivot 1.693, then R1 1.937.
Pattern-based odds: Similar-pattern stats imply modest upside bias (next day +0.4%, next week +2.61%, next month +3.2%), but these are small and not a strong edge.
Extremely oversold RSI can trigger a reflex bounce, especially since price is holding just above near-term support (~1.45).
No recent negative news flow in the past week (absence of fresh headlines can help stabilize microcaps after heavy selling).
Next earnings date is scheduled (2026-03-05 after hours), which can become a future volatility/catalyst window.
Neutral/Negative Catalysts
fails, with S2 around 1.297 as the next technical magnet.
Financial Performance
Latest quarter provided: 2025/Q3.
Revenue: 0 (0.00% YoY) — indicates no meaningful top-line traction in the snapshot provided.
Net income: -5.255M (improved 5.54% YoY) — losses narrowed slightly but the business is still meaningfully unprofitable.
EPS: -0.15 (down -21.05% YoY) — per-share performance worsened YoY despite the net income improvement (likely dilution/share count effects or other items).
Overall: financials do not yet show a clean growth inflection; the setup is more technical/speculative than fundamentals-driven.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No analyst rating or price target change data was provided, so Wall Street consensus trend cannot be confirmed from the dataset.
Practical pro view (inferred from what’s missing/available): without coverage/targets and with revenue at 0, institutional conviction is likely limited.
Practical con view: lack of visible fundamental momentum and absence of fresh catalysts reduces justification for buying aggressively today.
Politicians/Influential figures: No recent congress trading data available (no signal of notable political buying/selling in the last 90 days).
Wall Street analysts forecast BEAT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BEAT is 5.83 USD with a low forecast of 4 USD and a high forecast of 8 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast BEAT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BEAT is 5.83 USD with a low forecast of 4 USD and a high forecast of 8 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.290
Low
4
Averages
5.83
High
8
Current: 1.290
Low
4
Averages
5.83
High
8
Roth Capital
NULL -> Buy
initiated
$4
AI Analysis
2025-10-31
Reason
Roth Capital
Price Target
$4
AI Analysis
2025-10-31
initiated
NULL -> Buy
Reason
Roth Capital initiated coverage of HeartBeam with a Buy rating and $4 price target. The company is developing a credit-card-sized, cable-free cardiac device that synthesizes a 12-lead electrocardiogram, the analyst tells investors in a research note. The firm expects FDA clearance in the "coming days" that will initially focus on advanced cardiac arrhythmias within the concierge medicine market.
